Search Results - Application+%3e+Therapeutics

778 Results

Sort By:

Oxynitidine Derivatives Useful as Inhibitors of Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treating Cancer

Summary: The National Cancer Institute (NCI) is actively seeking potential licensees and/or co-development research collaboration partners interested in advancing oxynitidine derivatives as novel inhibitors of topoisomerase IB (TOP1) and tyrosyl-DNA phosphodiesterase 1 (TDP1) for cancer treatment. These TOPI and TDP1 inhibitors, when administered...

Published: 9/18/2024 | Inventor(s): Yves Pommier, Lin-kun An, Keli Agama, Evgeny Kiselev, Azhar Ravji

Keywords(s): Benzophenanthridine Derivatives, Benzophenanthridinone, Camptothecin, Dihydrobenzophenanthridine, IRINOTECAN, Oxynitidine, Pommier, Tdp1, TOP1, Topoisomerase 1B, Topotecan, Tyrosyl-DNA Phosphodiesterase 1

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics

TYROSINASE Gene Therapy for Oculocutaneous Albinism type 1A

Summary: The National Eye Institute seeks research co-development partners and/or licensees for an adeno-associated viral gene therapy for Oculocutaneous Albinism type 1A. Description of Technology: Oculocutaneous albinism (OCA) is a genetically heterogeneous congenital disorder characterized by decreased or absent pigmentation in the hair,...

Published: 8/14/2024 | Inventor(s): Brian Brooks, Aman George

Keywords(s):

Category(s): Application, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Eye / Ear / Nose / Throat, TherapeuticArea > Rare / Neglected Diseases, TherapeuticArea > Ophthalmology

Interleukin-27 Producing B-Cell Population and Uses Thereof

Summary: The National Eye Institute (NEI) seeks research co-development partners and/or licensees to advance the production and uses of interleukin-27 (IL-27) producing B-regulatory cell (i27-Breg) therapy for immune related autoimmune disorders. These disorders include but are not limited, to age-related macular degeneration (AMD), graft-versus-host...

Published: 8/14/2024 | Inventor(s): Charles Egwuagu, Jin Choi

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Eye / Ear / Nose / Throat, TherapeuticArea > Neurology, TherapeuticArea > Immunology

Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration

Summary: The National Eye Institute seeks research co-development partners and/or licensees for a therapy using an FDA-approved small molecule drug reserpine (and related compounds especially halofantrine) that prevents photoreceptor cell death in retinal degenerations. Description of Technology: Inherited Retinal Degenerations (IRD), such as Leber...

Published: 9/18/2024 | Inventor(s): Anand Swaroop, Yu Holly Chen, Samantha Papal, Anupam Mondal, Manju Swaroop, Wei Zheng, Gregory Tawa, Wenwei Huang, Zhiji Luo

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Eye / Ear / Nose / Throat

Immunogens, Compositions, and Methods for the Treatment of Dyslipidemia

This technology includes a novel vaccine for forming autoantibodies against apoC-III, a plasma enzyme that inhibits lipolysis. The vaccine can possibly be used to treat patients with high triglycerides and are at risk for pancreatitis and cardiovascular disease. This disclosure describes an ApoC3 immunogen that includes an antigenicApoC3 peptide linked...

Published: 8/12/2024 | Inventor(s): Alan Remaley

Keywords(s):

Category(s): Application > Research Materials, Application > Therapeutics, Application > Vaccines, Collaboration Sought > Licensing, ResearchProducts > Antibodies, TherapeuticArea > Metabolic Disease

Prazoles as Potential Broad Spectrum Anti-viral Agents

The technology described involves the use of a compound called prazole as an anti-viral agent specifically targeting HIV-1. It was found that prazole binds to a protein called Tsg101, which is crucial for the virus's life cycle. This binding disrupts the normal interaction of Tsg101 with another protein, ubiquitin, thereby inhibiting the release...

Published: 8/12/2024 | Inventor(s): Carol Carter, Lorna Ehrlich

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease

A Highly Efficient Differentiation Protocol for Placental Cells Derived from Human Pluripotent Stem Cells for Diagnostic and Therapeutic Applications

This technology includes in vitro-generated trophectoderm (TE) cells, which are ideal for modeling diseases of the placenta, drug screening, and cell-based therapies. The TE lineage which gives rise to placental cells during early human development. Derivation of definitive placental cells from human pluripotent stem cells in culture remains controversial...

Published: 8/12/2024 | Inventor(s): William Havel, Jeremy Newkirk, Rita Hadley, Yun Zhou

Keywords(s):

Category(s): Application > Diagnostics, Application > Research Materials, Application > Therapeutics, Collaboration Sought > Licensing, ResearchProducts > Human Cell Lines, ResearchProducts > Human iPSC Lines

Novel ApoC-11 Mimetic Peptides That Activate LPL for the Treatment of ApoC-11 Deficiency and Hypertriglyceridemia

This technology includes a new class of synthetic peptides that activate Lipoprotein Lipase (LPL), a key plasma enzyme that lowers triglycerides. Mutations in apoC-II is a genetic cause of severe hypertriglyceridemia, which can lead to cardiovascular disease and pancreatitis. The last helical domain (3rd helix) of apoC-ll activates LPL, and we discovered...

Published: 9/11/2024 | Inventor(s): Soumitra Ghosh, Chih-Hung (Larry) Lo, Alan Remaley, Denis Sviridov, Anna Wolska

Keywords(s):

Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Cardiology

Transgenic Mouse Expressing Cre for the Development for Delivery of Gene Therapy

This technology includes a mouse model containing a hypothetical, previously undescribed, gene that we have proven is expressed in hair cells of the inner ear and few other tissues in the body. The hair-cell limited expression of Cre is a genetic tool for creating conditional mutations affecting hair cells almost exclusively. Hair cells are the sensory...

Published: 8/12/2024 | Inventor(s): Robert Morell

Keywords(s):

Category(s): Application > Research Materials, Application > Therapeutics, ResearchProducts > Animal Models

Methods to Produce Very Long Chain Fatty Acids (VLCFA) for Use as Nutritional Formulas and as Therapeutics for Disease

This technology includes a new method to prepare very long chain fatty acids (VLCFA), which does not use the previously reported toxic mercury amalgam, for use as nutritional supplements, and as therapeutics for various diseases. The key coupling step involves an organocopper mediated coupling of the Grignard regent derived from the bromo alkyl tetraene...

Published: 9/11/2024 | Inventor(s): Rolf Swenson, Zhen-Dan Shi, Zhihong Yang, Alan Remaley

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Licensing

1 2 3 4 5 6 7 8 9 10 ...